Outcomes with Infliximab and Its Biosimilars in Patients with Rheumatoid Arthritis (RA): Real-World Experience in the US


Helfgott SM1, Radtchenko J2, Soloman N3, Huston K4, Singh JA5, Edgerton C6
1Brigham and Women's Hospital, Boston, MA, USA, 2Trio Health, Louisville, CO, USA, 3Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, USA, 4The Center for Rheumatic Disease & Allergy-Immunology, Kansas City, MO, USA, 5University of Alabama at Birmingham, Birmingham, AL, USA, 6Articularis Healthcare, Summerville, SC, USA

Presentation Documents


This study describes outcomes at 6 months among RA patients receiving infliximab and its biosimilars in US community rheumatology practices.


The study used electronic medical records from the American Rheumatology Network (ARN) - Trio Health Rheumatology registry. The ARN is a physician-led and owned organization with 200+ practicing rheumatologists in the US. Patients with RA diagnosis who initiated or switched to infliximab or biosimilars since Dec’2016 were selected for analysis. Logistic regression (LR) was used to evaluate binary outcome remission/low disease activity at 6 months (vs moderate/high) accounting for patient characteristics (age, payer, regimen, steroid use, number of prior regimens, and baseline disease activity).


Of 2806 patients, 1972 (70%) received infliximab and 834 (30%) biosimilars: infliximab-dyyb (69%) or infliximab-abda (31%). Compared to those on biosimilars, infliximab patients had significantly (p<.001) fewer prior synthetic disease-modifying antirheumatic drugs (DMARDs) or biologic regimens (mean regimens 1.4 (SD 1.8) vs 2.2 (1.9) infliximab-dyyb, 2 (1.6) infliximab-abda), were less likely to be Medicaid insured (4% vs 8% infliximab-dyyb, 24% infliximab-abda), were more likely to be in remission/low disease activity at treatment initiation (66% vs 43% infliximab-dyyb, 43% infliximab-abda) and at 6 months since treatment initiation (75% vs 60% infliximab-dyyb, 56% infliximab-abda).

In LR variables significantly associated the outcome were baseline disease activity (high/moderate vs low/remission: adjusted odds ratio (OR)=.09 CI .07-.14), payer type (Medicaid vs commercial: OR=.47 CI=.22-.99, and use of steroids (OR=.56 CI .40-.79) but not choice of a biologic (infliximab-abda vs infliximab OR=.91 CI .49-1.69, infliximab-dyyb vs infliximab OR=1.11 CI .74-1.65).


After accounting for patient characteristics, regimen choice was not significantly associated with treatment success at 6 months since regimen initiation.

Conference/Value in Health Info

2021-05, ISPOR 2021, Montreal, Canada

Value in Health, Volume 24, Issue 5, S1 (May 2021)




Clinical Outcomes, Real World Data & Information Systems

Topic Subcategory

Clinical Outcomes Assessment, Distributed Data & Research Networks


Musculoskeletal Disorders

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now